EX-HYPO

CompletedPhase NA

The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes

Examining the Effect of Endogenous Glucagon-like Peptide-1 on Glucagon Secretion in Type 1 Diabetes

Lead sponsor

Asger Lund, MD

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Eligibility highlights

•BMI 19-30•Male

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07373236

Org study IDH-25032390

Timeline

Milestones

Study start2026-01-23actual

Study first posted2026-01-28actual

Primary completion2026-04-09actual

Study completion2026-04-09actual

Last update posted2026-04-29actual

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexMale

Healthy volunteersNot accepted

Inclusion criteria

•Caucasian ethnicity

•Age between 18 and 70 years

•T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c <69 mmol/mol (<8.5%)

•Body mass index between 19 and 30 kg/m2

•T1D duration of 2-30 years

•C-peptide negative (5 gram arginine-stimulated C-peptide ≤100 pmol/l)

•Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months

Exclusion criteria

•Anaemia (haemoglobin below normal range)

•Late microvascular complications except mild non-proliferative retinopathy

•Liver disease (Evaluated by alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) >2 times normal values) or a history of hepatobiliary disorder

•Kidney disease (serum creatinine above normal range)

•Treatment with any glucose-lowering drugs beside insulin

•Active or recent (within 5 years) malignant disease

•Regular tobacco smoking or use of other nicotine-containing products

•Any condition considered incompatible with participation by the investigators.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.